- Home
- SPHR vs ADPT Comparison
SPHR vs ADPT Comparison
Compare SPHR & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHR
- ADPT
- Stock Information
- Founded
- SPHR 2020
- ADPT 2009
- Country
- SPHR United States
- ADPT United States
- Employees
- SPHR N/A
- ADPT N/A
- Industry
- SPHR Services-Misc. Amusement & Recreation
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SPHR Consumer Discretionary
- ADPT Health Care
- Exchange
- SPHR Nasdaq
- ADPT Nasdaq
- Market Cap
- SPHR 1.3B
- ADPT 1.4B
- IPO Year
- SPHR N/A
- ADPT 2019
- Fundamental
- Price
- SPHR $38.56
- ADPT $10.38
- Analyst Decision
- SPHR Buy
- ADPT Strong Buy
- Analyst Count
- SPHR 10
- ADPT 7
- Target Price
- SPHR $46.70
- ADPT $10.57
- AVG Volume (30 Days)
- SPHR 527.8K
- ADPT 1.3M
- Earning Date
- SPHR 08-13-2025
- ADPT 07-31-2025
- Dividend Yield
- SPHR N/A
- ADPT N/A
- EPS Growth
- SPHR N/A
- ADPT N/A
- EPS
- SPHR N/A
- ADPT N/A
- Revenue
- SPHR $1,031,650,000.00
- ADPT $189,527,000.00
- Revenue This Year
- SPHR $9.19
- ADPT $24.46
- Revenue Next Year
- SPHR $6.40
- ADPT $20.25
- P/E Ratio
- SPHR N/A
- ADPT N/A
- Revenue Growth
- SPHR 16.89
- ADPT 8.61
- 52 Week Low
- SPHR $23.89
- ADPT $2.99
- 52 Week High
- SPHR $50.88
- ADPT $10.87
- Technical
- Relative Strength Index (RSI)
- SPHR 57.23
- ADPT 62.28
- Support Level
- SPHR $37.94
- ADPT $9.90
- Resistance Level
- SPHR $40.06
- ADPT $10.85
- Average True Range (ATR)
- SPHR 1.18
- ADPT 0.48
- MACD
- SPHR -0.26
- ADPT -0.02
- Stochastic Oscillator
- SPHR 50.56
- ADPT 68.39
About SPHR Sphere Entertainment Co.
Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments which includeSphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).